GSA Capital Partners LLP Invests $1.67 Million in Privia Health Group, Inc. $PRVA

GSA Capital Partners LLP bought a new stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65,048 shares of the company’s stock, valued at approximately $1,674,000. GSA Capital Partners LLP owned about 0.05% of Privia Health Group as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Privia Health Group by 14.0% during the 2nd quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock valued at $124,000 after purchasing an additional 592 shares during the last quarter. State of Alaska Department of Revenue raised its stake in Privia Health Group by 1.3% in the fourth quarter. State of Alaska Department of Revenue now owns 65,747 shares of the company’s stock valued at $1,558,000 after buying an additional 823 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Privia Health Group by 8.8% in the first quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock valued at $213,000 after buying an additional 840 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Privia Health Group by 4.1% in the fourth quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock worth $535,000 after acquiring an additional 898 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in Privia Health Group by 5.9% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock worth $385,000 after acquiring an additional 903 shares in the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Matthew Shawn Morris sold 53,722 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $27.24, for a total transaction of $1,463,387.28. Following the transaction, the director directly owned 68,188 shares in the company, valued at $1,857,441.12. The trade was a 44.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Mountcastle sold 21,275 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $27.67, for a total value of $588,679.25. Following the completion of the sale, the chief financial officer owned 164,853 shares of the company’s stock, valued at $4,561,482.51. This trade represents a 11.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 327,886 shares of company stock valued at $8,628,256. 5.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Barclays cut their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Canaccord Genuity Group set a $32.00 target price on shares of Privia Health Group in a research note on Friday, August 7th. Zacks Research upgraded shares of Privia Health Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 5th. Weiss Ratings raised shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Finally, Citigroup reissued a “buy” rating on shares of Privia Health Group in a report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Privia Health Group has an average rating of “Moderate Buy” and an average price target of $31.00.

Privia Health Group Price Performance

Shares of Privia Health Group stock opened at $22.00 on Monday. The stock has a market cap of $2.81 billion, a PE ratio of 104.77, a price-to-earnings-growth ratio of 1.77 and a beta of 0.85. The firm has a fifty day moving average price of $24.71 and a 200 day moving average price of $23.28. Privia Health Group, Inc. has a 1 year low of $19.53 and a 1 year high of $28.82.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.